دورية أكاديمية
L-type amino acid transporter (LAT) 1 expression in 18 F-FET-negative gliomas.
| العنوان: | L-type amino acid transporter (LAT) 1 expression in 18 F-FET-negative gliomas. |
|---|---|
| المؤلفون: | Vettermann FJ; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany. Franziska.vettermann@med.uni-muenchen.de., Diekmann C; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany., Weidner L; Department of Neuropathology, Regensburg University Hospital, Regensburg, Germany., Unterrainer M; Department of Radiology, University Hospital of Munich, LMU Munich, Munich, Germany., Suchorska B; Department of Neurosurgery, University Hospital of Munich, LMU Munich, Munich, Germany.; Department of Neurosurgery, Sana Hospital, Duisburg, Germany., Ruf V; Center for Neuropathology, University Hospital of Munich, LMU Munich, Munich, Germany., Dorostkar M; Center for Neuropathology, University Hospital of Munich, LMU Munich, Munich, Germany., Wenter V; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany., Herms J; Center for Neuropathology, University Hospital of Munich, LMU Munich, Munich, Germany., Tonn JC; Department of Neurosurgery, University Hospital of Munich, LMU Munich, Munich, Germany.; German Cancer Consortium (DKTK), Partner Site Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany., Bartenstein P; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany.; German Cancer Consortium (DKTK), Partner Site Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany., Riemenschneider MJ; Department of Neuropathology, Regensburg University Hospital, Regensburg, Germany., Albert NL; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany.; German Cancer Consortium (DKTK), Partner Site Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany. |
| المصدر: | EJNMMI research [EJNMMI Res] 2021 Dec 14; Vol. 11 (1), pp. 124. Date of Electronic Publication: 2021 Dec 14. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer Berlin Country of Publication: Germany NLM ID: 101560946 Publication Model: Electronic Cited Medium: Print ISSN: 2191-219X (Print) Linking ISSN: 2191219X NLM ISO Abbreviation: EJNMMI Res Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Heidelberg : Springer Berlin |
| مستخلص: | Background: O-(2-[ 18 F]-fluoroethyl)-L-tyrosine ( 18 F-FET) is a highly sensitive PET tracer for glioma imaging, and its uptake is suggested to be driven by an overexpression of the L-type amino-acid transporter 1 (LAT1). However, 30% of low- and 5% of high-grade gliomas do not present enhanced 18 F-FET uptake at primary diagnosis (" 18 F-FET-negative gliomas") and the pathophysiologic basis for this phenomenon remains unclear. The aim of this study was to determine the expression of LAT1 in a homogeneous group of newly diagnosed 18 F-FET-negative gliomas and to compare them to a matched group of 18 F-FET-positive gliomas. Forty newly diagnosed IDH-mutant astrocytomas without 1p/19q codeletion were evaluated (n = 20 18 F-FET-negative (tumour-to-background ratio (TBR) < 1.6), n = 20 18 F-FET-positive gliomas (TBR > 1.6)). LAT1 immunohistochemistry (IHC) was performed using SLC7A5/LAT1 antibody. The percentage of LAT1-positive tumour cells (%) and the staining intensity (range 0-2) were multiplied to an overall score (H-score; range 0-200) and correlated to PET findings as well as progression-free survival (PFS). Results: IHC staining of LAT1 expression was positive in both, 18 F-FET-positive as well as 18 F-FET-negative gliomas. No differences were found between the 18 F-FET-negative and 18 F-FET-positive group with regard to percentage of LAT1-positive tumour cells, staining intensity or H-score. Interestingly, the LAT1 expression showed a significant negative correlation with the PFS (p = 0.031), whereas no significant correlation was found for TBR Conclusion: Although LAT1 is reported to mediate the uptake of 18 F-FET into tumour cells, the levels of LAT1 expression do not correlate with the levels of 18 F-FET uptake in IDH-mutant astrocytomas. In particular, the lack of tracer uptake in 18 F-FET-negative gliomas cannot be explained by a reduced LAT1 expression. A higher LAT1 expression in IDH-mutant astrocytomas seems to be associated with a short PFS. Further studies regarding mechanisms influencing the uptake of 18 F-FET are necessary. (© 2021. The Author(s).) |
| References: | J Nucl Med. 2004 Sep;45(9):1591-6. (PMID: 15347729) Brain Res. 2007 May 25;1147:25-33. (PMID: 17343835) Lancet Oncol. 2011 Jun;12(6):583-93. (PMID: 21474379) BMC Cancer. 2013 Oct 16;13:482. (PMID: 24131658) J Nucl Med. 2005 Dec;46(12):1948-58. (PMID: 16330557) Clin Nucl Med. 2017 Dec;42(12):e506-e508. (PMID: 29076908) J Nucl Med. 2014 Feb;55(2):198-203. (PMID: 24379223) Histopathology. 2009 Jun;54(7):804-13. (PMID: 19635099) Neuro Oncol. 2019 Dec 17;21(12):1612-1613. (PMID: 31504819) Nature. 2019 Apr;568(7750):127-130. (PMID: 30867591) Neurosurgery. 2008 Feb;62(2):493-503; discussion 503-4. (PMID: 18382329) J Neurooncol. 2013 Jan;111(1):11-8. (PMID: 23086431) J Neurooncol. 2008 Jun;88(2):205-10. (PMID: 18317691) Int J Mol Sci. 2020 Jan 17;21(2):. (PMID: 31963507) J Nucl Med. 2015 Jan;56(1):9-15. (PMID: 25537990) Br J Cancer. 2008 Feb 26;98(4):742-8. (PMID: 18253116) Virchows Arch. 2019 Jun;474(6):701-710. (PMID: 30637450) J Clin Oncol. 2017 Jul 20;35(21):2439-2449. (PMID: 28640707) Neuro Oncol. 2019 Oct 9;21(10):1221-1222. (PMID: 31278863) Neuro Oncol. 2016 Sep;18(9):1199-208. (PMID: 27106405) Hepatol Res. 2015 Sep;45(9):1014-1022. (PMID: 25297701) J Neurooncol. 2010 Sep;99(2):217-25. (PMID: 20091333) Clin Nucl Med. 2021 Jan;46(1):e36-e37. (PMID: 32804767) Breast Cancer Res. 2018 Mar 22;20(1):21. (PMID: 29566741) Nucl Med Biol. 2006 Apr;33(3):287-94. (PMID: 16631076) Int J Cancer. 2006 Aug 1;119(3):484-92. (PMID: 16496379) Neuro Oncol. 2019 Oct 9;21(10):1331-1338. (PMID: 31077276) Brain Tumor Pathol. 2005;22(2):89-91. (PMID: 18095110) Eur J Nucl Med Mol Imaging. 2012 Jun;39(6):1021-9. (PMID: 22491781) Eur J Nucl Med Mol Imaging. 2008 Nov;35(11):2009-17. (PMID: 18542957) J Nucl Med. 2007 Dec;48(12):2063-71. (PMID: 18056335) PLoS One. 2020 May 29;15(5):e0233629. (PMID: 32469987) J Nucl Med. 2016 Aug;57(8):1177-82. (PMID: 27033893) Pathol Int. 2009 Jan;59(1):7-18. (PMID: 19121087) Cell Discov. 2021 Mar 23;7(1):16. (PMID: 33758168) Amino Acids. 2015 Feb;47(2):335-44. (PMID: 25385314) Anticancer Res. 2010 Dec;30(12):4819-28. (PMID: 21187458) J Surg Oncol. 2016 Mar;113(4):381-9. (PMID: 26936531) Front Chem. 2020 Oct 20;8:564809. (PMID: 33195053) Virchows Arch. 2006 Feb;448(2):142-50. (PMID: 16175382) BMC Clin Pathol. 2012 Feb 28;12:4. (PMID: 22373026) J Nucl Med. 2017 Jan;58(1):129-137. (PMID: 27469356) Acta Neuropathol. 2016 Jun;131(6):803-20. (PMID: 27157931) J Clin Oncol. 2003 Oct 15;21(20):3798-807. (PMID: 12953099) Oncol Lett. 2017 Dec;14(6):7410-7416. (PMID: 29344181) Cancer. 2001 Sep 15;92(6):1541-9. (PMID: 11745233) Brain. 2005 Mar;128(Pt 3):678-87. (PMID: 15689365) |
| فهرسة مساهمة: | Keywords: FET PET; Glioma; LAT1; Molecular imaging |
| تواريخ الأحداث: | Date Created: 20211214 Latest Revision: 20211218 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC8671595 |
| DOI: | 10.1186/s13550-021-00865-9 |
| PMID: | 34905134 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 2191-219X |
|---|---|
| DOI: | 10.1186/s13550-021-00865-9 |